NGEN
NervGen Pharma Corp. Common stock NASDAQ Listed Feb 8, 2021$2.17
+3.67%
vs $2.09
Mkt Cap $178.1M
52w Low $1.70
10.1% of range
52w High $6.30
50d MA $2.81
200d MA $3.57
P/E (TTM)
—
EV/EBITDA
—
P/B
45.0x
Debt/Equity
0.0x
ROE
—
P/FCF
-7.8x
RSI (14)
65.80
ATR (14)
$0.17
Beta
0.99
50d MA
$2.81
200d MA
$3.57
Avg Volume
1.4M
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.
1455 Bellevue Avenue, Suite 301 · West Vancouver, BC V7T 1C3 · CA
Data updated apr 26, 2026 2:55pm
· Source: financialmodelingprep.com